Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 3/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26175287 | 0.88 | KIT (0.58) | TGFBR1KITAXLFLT3MERTK | |
| SCHEMBL26175489 | 0.86 | AXL (0.43) | KITAXLCDK8TNIKDYRK1A | |
| SCHEMBL26175560 | 0.85 | NTRK1 (0.46) | KITAXLCDK8TNIKDYRK1A | |
| SCHEMBL26175246 | 0.84 | AXL (0.64) | KITAXLCDK8TNIKDYRK1A | |
| SCHEMBL26174736 | 0.83 | PDE4A (0.45) | TGFBR1KITAXLCDK8TNIK | |
| SCHEMBL26175523 | 0.83 | NTRK1 (0.48) | KITAXLCDK8TNIKDYRK1A | |
| SCHEMBL26175448 | 0.83 | KIT (0.58) | KITAXLCDK8TNIKDYRK1A | |
| SCHEMBL26175494 | 0.82 | KIT (0.44) | TGFBR1KITAXLCDK8TNIK | |
| SCHEMBL15730182 | 0.82 | TGFBR1 (0.64) | TGFBR1AXLFLT3MERTKDYRK1A | |
| SCHEMBL26174699 | 0.81 | CYP1A2 (0.47) | TGFBR1KITAXLCDK8TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | TGFBR1 2134/4885KIT 4356/4885AXL 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.